{"id":"https://openalex.org/W2806768517","doi":"https://doi.org/10.1016/s1569-1993(18)30295-9","title":"IPD2.11 The potentially beneficial CNS-activity profile of ivacaftor and its metabolites","display_name":"IPD2.11 The potentially beneficial CNS-activity profile of ivacaftor and its metabolites","publication_year":2018,"publication_date":"2018-06-01","ids":{"openalex":"https://openalex.org/W2806768517","doi":"https://doi.org/10.1016/s1569-1993(18)30295-9","mag":"2806768517"},"language":"en","primary_location":{"id":"doi:10.1016/s1569-1993(18)30295-9","doi":"https://doi.org/10.1016/s1569-1993(18)30295-9","is_oa":true,"landing_page_url":"https://doi.org/10.1016/s1569-1993(18)30295-9","pdf_url":"https://doi.org/10.1016/s1569-1993(18)30295-9","source":{"id":"https://openalex.org/S147774598","display_name":"Journal of Cystic Fibrosis","issn_l":"1569-1993","issn":["1569-1993","1873-5010"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Cystic Fibrosis","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://doi.org/10.1016/s1569-1993(18)30295-9","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110083412","display_name":"E. Schneider","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Schneider","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027851081","display_name":"Vincenzo Carbone","orcid":"https://orcid.org/0000-0003-4231-2785","observed_orcids":["https://orcid.org/0000-0003-4231-2785"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. Carbone","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059010278","display_name":"John W. Wilson","orcid":"https://orcid.org/0000-0003-2118-3646","observed_orcids":["https://orcid.org/0000-0003-2118-3646"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Wilson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062625452","display_name":"Brenda Button","orcid":"https://orcid.org/0000-0002-3044-8872","observed_orcids":["https://orcid.org/0000-0002-3044-8872"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Button","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089197450","display_name":"Dani\u00ebl Hoyer","orcid":"https://orcid.org/0000-0002-1405-7089","observed_orcids":["https://orcid.org/0000-0002-1405-7089"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Hoyer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112282836","display_name":"J. Li","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5020748618","display_name":"Tony Velkov","orcid":"https://orcid.org/0000-0002-0017-7952","observed_orcids":["https://orcid.org/0000-0002-0017-7952"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Velkov","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4370,"currency":"USD","value_usd":4370},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.09313514,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":"S56","last_page":"S56"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10665","display_name":"Cystic Fibrosis Research Advances","score":0.8568999767303467,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10665","display_name":"Cystic Fibrosis Research Advances","score":0.8568999767303467,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.010200000368058681,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.009600000455975533,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ivacaftor","display_name":"ivacaftor","score":0.9810000061988831},{"id":"https://openalex.org/keywords/lumacaftor-ivacaftor","display_name":"lumacaftor/ivacaftor","score":0.8949999809265137},{"id":"https://openalex.org/keywords/f508del-cftr","display_name":"F508del-CFTR","score":0.9309999942779541},{"id":"https://openalex.org/keywords/cftr-modulator-therapy","display_name":"CFTR modulator therapy","score":0.7350000143051147},{"id":"https://openalex.org/keywords/fev1-decline","display_name":"FEV1 decline","score":0.8539999723434448},{"id":"https://openalex.org/keywords/lung-function","display_name":"lung function","score":0.7559999823570251},{"id":"https://openalex.org/keywords/body-mass-index","display_name":"body mass index","score":0.878000020980835},{"id":"https://openalex.org/keywords/antibiotic-use","display_name":"antibiotic use","score":0.7139999866485596},{"id":"https://openalex.org/keywords/advanced-lung-disease","display_name":"advanced lung disease","score":0.781000018119812}],"concepts":[{"id":"https://openalex.org/C2776502428","wikidata":"https://www.wikidata.org/wiki/Q6095693","display_name":"Ivacaftor","level":4,"score":0.985065221786499},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8913925886154175},{"id":"https://openalex.org/C2776938444","wikidata":"https://www.wikidata.org/wiki/Q178194","display_name":"Cystic fibrosis","level":2,"score":0.8803979158401489},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.36159810423851013},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.22145840525627136},{"id":"https://openalex.org/C2778428886","wikidata":"https://www.wikidata.org/wiki/Q420470","display_name":"Cystic fibrosis transmembrane conductance regulator","level":3,"score":0.04837590456008911}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s1569-1993(18)30295-9","doi":"https://doi.org/10.1016/s1569-1993(18)30295-9","is_oa":true,"landing_page_url":"https://doi.org/10.1016/s1569-1993(18)30295-9","pdf_url":"https://doi.org/10.1016/s1569-1993(18)30295-9","source":{"id":"https://openalex.org/S147774598","display_name":"Journal of Cystic Fibrosis","issn_l":"1569-1993","issn":["1569-1993","1873-5010"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Cystic Fibrosis","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/s1569-1993(18)30295-9","doi":"https://doi.org/10.1016/s1569-1993(18)30295-9","is_oa":true,"landing_page_url":"https://doi.org/10.1016/s1569-1993(18)30295-9","pdf_url":"https://doi.org/10.1016/s1569-1993(18)30295-9","source":{"id":"https://openalex.org/S147774598","display_name":"Journal of Cystic Fibrosis","issn_l":"1569-1993","issn":["1569-1993","1873-5010"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Cystic Fibrosis","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2806768517.pdf","grobid_xml":"https://content.openalex.org/works/W2806768517.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2805856625","https://openalex.org/W2805067127","https://openalex.org/W2806192671","https://openalex.org/W2947581345","https://openalex.org/W2767840926","https://openalex.org/W3033171841","https://openalex.org/W3033108840","https://openalex.org/W2615423082","https://openalex.org/W3033330499","https://openalex.org/W4254987927"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2018-06-13T00:00:00"}